Emyria Limited (ASX: EMD) Webcast Replay
Emyria Limited (ASX: EMD) is a data-backed, drug development company. Emyria’s Treatments target unmet needs and are focused on obtaining approval from major global regulators.
As a part of our ‘The Insiders: Meet the CEOs’ series, CEO Dr Michael Winlo provides valuable insights to the company, its key markets and industry, and future prospects.
Recorded on 17 February 2021 at 12pm (AEDT).
Join the next The Insider: Meet the CEOs webcast
FEATURED SPEAKER
Dr Michael Winlo
Chief Executive Officer - Emyria Limited (ASX: EMD)
Emyria Limited (ASX: EMD) is a data-backed, drug development company. Emyria’s Treatments target unmet needs and are focused on obtaining approval from major global regulators. Emyria’s drug development programs are informed by insights generated from extensive analysis of Emyria Data – deep, ethically-sourced clinical evidence that is gathered with patients across Emyria’s independent clinical services.
Emyria Data provides deep treatment insights and is therefore a source of unique IP, strategically designed drug development and personalised care programs.
